Thermo Fisher's Q3 earnings boosted by COVID-19 sales October 21, 2020 -- Products related to the novel coronavirus are spelling success for Thermo Fisher, which reported that revenue was up by 36% in the third quarter to $8.52 billion, compared with $6.27 billion the same period last year.
Reaction Biology, 4HF Biotec offer new cell-based services October 19, 2020 -- Reaction Biology and 4HF Biotec announced that they are offering a new cell-based service that will give customers a comprehensive understanding of their candidates. The service will combine Reaction's ProLiFiler cell assay service with 4HF's Biomarker Analysis and Mode of Action (MoA) Finder tools
Precigen nabs FDA nod for manufacturing UltraCAR-T therapies October 15, 2020 -- Precigen has been granted clearance by the U.S. Food and Drug Administration (FDA) for its UltraPorator system. The system also had a successful technology transfer to clinical sites and will be used as a manufacturing device for Precigen's investigational UltraCAR-T therapies.
Qiagen sales, earnings climb in Q3 October 14, 2020 -- Significant ongoing demand for COVID-19 testing and improved trends in other areas of Qiagen's product portfolio led to a 26% increase in preliminary net sales for the company during its third quarter.
Dyno Therapeutics licenses AAV platform to Roche October 14, 2020 -- Dyno Therapeutics has licensed its CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies to Roche and its subsidiary Spark Therapeutics.